369 related articles for article (PubMed ID: 28893612)
1. Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.
Wu CP; Hsiao SH; Murakami M; Lu MJ; Li YQ; Hsieh CH; Ambudkar SV; Wu YS
Cancer Lett; 2017 Nov; 409():56-65. PubMed ID: 28893612
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
3. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Mol Pharm; 2019 Jul; 16(7):3040-3052. PubMed ID: 31117741
[TBL] [Abstract][Full Text] [Related]
4. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
[TBL] [Abstract][Full Text] [Related]
5. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
Wu CP; Murakami M; Hsiao SH; Liu TC; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV
Cancer Lett; 2018 Oct; 433():259-272. PubMed ID: 30026175
[TBL] [Abstract][Full Text] [Related]
6. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
7. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.
Shi Z; Tiwari AK; Shukla S; Robey RW; Kim IW; Parmar S; Bates SE; Si QS; Goldblatt CS; Abraham I; Fu LW; Ambudkar SV; Chen ZS
Biochem Pharmacol; 2009 Mar; 77(5):781-93. PubMed ID: 19059384
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
11. The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.
Wu CP; Murakami M; Wu YS; Lin CL; Li YQ; Huang YH; Hung TH; Ambudkar SV
Biomed Pharmacother; 2022 May; 149():112922. PubMed ID: 36068781
[TBL] [Abstract][Full Text] [Related]
12. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
[TBL] [Abstract][Full Text] [Related]
13. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
Patel A; Tiwari AK; Chufan EE; Sodani K; Anreddy N; Singh S; Ambudkar SV; Stephani R; Chen ZS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):189-99. PubMed ID: 23673445
[TBL] [Abstract][Full Text] [Related]
14. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
[TBL] [Abstract][Full Text] [Related]
15. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Shukla S; Robey RW; Bates SE; Ambudkar SV
Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
[TBL] [Abstract][Full Text] [Related]
17. The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905792
[TBL] [Abstract][Full Text] [Related]
18. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
Sorf A; Hofman J; Kučera R; Staud F; Ceckova M
Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999
[TBL] [Abstract][Full Text] [Related]
19. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2.
Wu CP; Hsieh YJ; Tseng HY; Huang YH; Li YQ; Hung TH; Wang SP; Wu YS
Biomed Pharmacother; 2022 Oct; 154():113663. PubMed ID: 36081287
[TBL] [Abstract][Full Text] [Related]
20. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
